POAI: Predictive Oncology, Inc.
About
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
Current Value
$0.691 Year Return
Current Value
$0.691 Year Return
Key Details
Market Cap
$4.59M
P/E Ratio
-0.23
1Y Stock Return
-76.64%
1Y Revenue Growth
-23.75%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include POAI
Stock's related to POAI
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LTM | 60.47% | $8.37B | -100.00% | <0.01% |
| TCS | 31.79% | $13.39M | -86.02% | 0.00% |
| GSHD | 31.05% | $2.98B | +69.11% | 0.00% |
| BALY | 30.69% | $722.24M | +48.00% | 0.00% |
| TYL | 29.85% | $25.56B | +45.00% | 0.00% |
| RTX | 28.66% | $160.43B | +51.00% | 2.05% |
| RIG | 26.57% | $3.80B | -31.00% | 0.00% |
| CLB | 26.54% | $991.59M | +16.11% | 0.19% |
| UL | 26.48% | $142.68B | +20.62% | 3.20% |
| INSM | 26.43% | $13.20B | +211.04% | 0.00% |
| FCF | 26.43% | $1.91B | +40.69% | 2.74% |
| DAR | 26.34% | $6.55B | -4.79% | 0.00% |
| SBSI | 25.85% | $1.06B | +25.02% | 5.08% |
| BJRI | 25.75% | $787.63M | +12.19% | 0.00% |
| NOC | 25.63% | $72.32B | +5.29% | 1.58% |
| SEG | 25.09% | $344.46M | +21.11% | 0.00% |
| TRU | 24.70% | $19.24B | +66.75% | 0.32% |
| NOW | 24.69% | $215.69B | +56.36% | 0.00% |
| PLRX | 24.54% | $781.97M | -7.75% | 0.00% |
| UHS | 24.45% | $13.04B | +42.80% | 0.41% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GPC | -<0.01% | $17.06B | -10.95% | 3.20% |
| CDNS | -<0.01% | $84.06B | +13.38% | 0.00% |
| OMAB | -<0.01% | $2.76B | -3.93% | 7.29% |
| ELF | <0.01% | $6.90B | +7.66% | 0.00% |
| RARE | -0.01% | $4.25B | +20.44% | 0.00% |
| HMST | 0.02% | $212.90M | +85.39% | 0.00% |
| ROAD | 0.02% | $5.12B | +123.52% | 0.00% |
| VSTS | 0.02% | $2.05B | -6.47% | 0.90% |
| GHM | 0.03% | $472.08M | +129.73% | 0.00% |
| ARMK | -0.03% | $10.65B | +43.69% | 0.94% |
| JMIA | -0.04% | $372.14M | +14.47% | 0.00% |
| SNPS | 0.04% | $85.71B | +3.13% | 0.00% |
| IRTC | -0.05% | $2.31B | -14.88% | 0.00% |
| V | -0.06% | $591.57B | +22.14% | 0.70% |
| IDXX | -0.06% | $34.27B | -12.50% | 0.00% |
| EPC | -0.06% | $1.71B | +0.75% | 1.71% |
| CMG | -0.08% | $81.73B | +35.16% | 0.00% |
| BTCT | -0.08% | $58.86M | +395.83% | 0.00% |
| ADBE | -0.08% | $222.05B | -18.60% | 0.00% |
| SSRM | -0.08% | $1.21B | -46.80% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EW | -46.52% | $41.51B | +4.95% | 0.00% |
| RSG | -31.32% | $67.03B | +33.78% | 1.01% |
| WM | -28.19% | $88.91B | +28.97% | 1.33% |
| LKQ | -25.37% | $9.85B | -17.18% | 3.13% |
| WST | -25.02% | $23.24B | -8.63% | 0.25% |
| ITGR | -24.83% | $4.56B | +52.23% | 0.00% |
| ORN | -22.93% | $339.61M | +78.16% | 0.00% |
| MXL | -21.40% | $1.33B | -12.26% | 0.00% |
| F | -18.60% | $42.92B | +6.79% | 5.51% |
| ALL | -16.95% | $53.88B | +49.52% | 1.80% |
| INVH | -16.54% | $20.72B | +1.35% | 3.30% |
| GTX | -15.77% | $1.75B | +9.63% | 0.00% |
| BSX | -14.95% | $134.86B | +65.07% | 0.00% |
| LULU | -14.82% | $38.69B | -26.48% | 0.00% |
| CHD | -14.66% | $27.50B | +19.29% | 1.01% |
| SIMO | -14.60% | $1.83B | -7.71% | 3.67% |
| MMM | -14.29% | $69.33B | +59.68% | 2.84% |
| RNR | -13.86% | $13.75B | +22.34% | 0.58% |
| VVI | -13.41% | $915.71M | +34.30% | 0.00% |
| ICLR | -13.02% | $17.57B | -21.76% | 0.00% |
ETF's related to POAI
News
Yahoo
Predictive Oncology ( NASDAQ:POAI ) Third Quarter 2024 Results Key Financial Results Revenue: US$345.7k (down 52% from...
Yahoo
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder valuePITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended S
Yahoo
Despite a decline in revenue, Predictive Oncology Inc (POAI) strengthens its AI capabilities and financial position through strategic initiatives and collaborations.
Yahoo
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY. Management’s presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. The Predicti
Yahoo
Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples Global biospecimen market valued at $4.4 billion in 2023, expected to grow at an annual CAGR of more than 13%, reaching $11.7 billion by 20311 PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced the results of a successful study that demonstrates the long-term stabil
Yahoo
We feel now is a pretty good time to analyse Predictive Oncology Inc.'s ( NASDAQ:POAI ) business as it appears the...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.